Real-World check: does new hair loss drug deliver outside of trials?

This study examines how patients with severe alopecia areata (an autoimmune disease causing hair loss) are using ritlecitinib in real-world clinics, not just in controlled trials. Researchers will look at medical records of about 300 people aged 12 and older who started the drug between July 2023 and February 2025. The goal is to see how much hair regrows and how patients' quality of life changes, especially for groups often left out of earlier studies.